Catamaran Bio: Scott Holmes
Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies, has appointed Scott Holmes, MS, MBA, as Chief Financial Officer.
Holmes has 20 years of experience in finance, strategy, and operations: including the role of CFO at other biotechs where he led high-value financings and transactions.
Most recently, Holmes was CFO of Disarm Therapeutics, where he was responsible for all financial operations and played a key role in the company’s acquisition by Eli Lilly in October 2020.
Previously, he was CFO of the publicly-traded cell therapy biotech, Kiadis Pharma, including leading the company’s acquisition of CytoSen Therapeutics.
He spent four years as CFO of Keryx Biopharmaceuticals, where he executed multiple high-value financial offerings and oversaw the merger of Keryx into Akebia Therapeutics. Holmes was also previously SVP of Finance and Investor Relations at AMAG Pharmaceuticals.
Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Its capabilities are designed to take the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness through synthetic biology and innovative non-viral cell engineering; led by its Tailwind Platform.
